ReviewCureus2025
Effectiveness of Prothrombin Complex Concentrate Versus Fresh Frozen Plasma in Major Cardiac Surgeries: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major bleeding is a common and important complication following major cardiac surgeries. Fresh frozen plasma (FFP) is the standard therapy for bleeding-related complications. Prothrombin complex concentrate (PCC) may offer a good alternative during cardiac surgeries. We aimed to assess whether PCC could potentially replace FFP in clinical practice. We searched different databases from inception until July 2025 for only randomized controlled trials (RCTs) that compared PCC with FFP in patients undergoing major cardiac surgeries and assessed our outcomes of interest in an intention-to-treat analysis. The primary outcome of interest was the change in international normalized ratio (INR). Data were pooled as risk ratio (RR) and mean difference (MD) with their 95% confidence intervals (CIs). A total of six RCTs with 761 patients were included in the final analysis. Patients allocated to PCC had lower INR values compared to those allocated to FFP (MD = -0.13, 95% CI: -0.18 to -0.07, p < 0.001). Additionally, PCC administration was associated with less blood drained from chest tubes (MD = -157.06 mL, 95% CI: -252.92 to -61.19, p < 0.001), fewer transfused RBC units (MD = -0.95, 95% CI: -1.25 to -0.65, p < 0.001), and higher hemostatic effectiveness rates (RR = 1.18, 95% CI: 1.02 to 1.36, p = 0.03). No significant differences were observed regarding safety measures. In patients undergoing major cardiac surgeries, the use of PCC showed superior effectiveness over FFP regarding hemostatic efficacy and other related outcomes. Also, PCC demonstrated similar safety measures compared to FFP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.